Ask AI
ProCE Banner Activity

Experts Answer Questions on HER2-Targeted ADCs in HER2-Positive Advanced Bladder Cancer

Clinical Thought

In this commentary, experts on urothelial cancers address topics selected by a healthcare professional audience on effectively incorporating HER2 antibody–drug conjugates into clinical practice for patients with HER2-positive advanced urothelial carcinoma.

Released: December 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of urologists, oncologists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess HER2 alterations in patients with bladder cancer to guide individualized clinical decisions

  • Evaluate the latest efficacy and safety data for HER2-targeted ADCs in bladder cancer to inform personalized treatment plans and supportive care for treatment-related adverse events (TRAEs)

  • Formulate care strategies for HER2 expressing bladder cancer that are informed by available clinical evidence and expert recommendations

Disclosure

Primary Author

Matthew D. Galsky, MD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Merck, Pfizer.

Vadim S. Koshkin, MD: consultant/advisor/speaker: Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Janssen, Loxo Oncology, Merck, Natera, Pfizer, Roche/Genentech, Tempus; researcher: Lilly.